

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7704272

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MAXENCE BOS	05/17/2021
JOHN MANCUSO	05/17/2021
IVAN FRANZONI	05/17/2021
RECEIVING PARTY DATA	
Name:	NUCHEM THERAPEUTICS INC.
Street Address:	2350 COHEN STREET, SUITE 201
City:	SAINT-LAURENT, QUEBEC
State/Country:	CANADA
Postal Code:	H4R 2N6
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	18072501
CORRESPONDENCE DATA	
Fax Number:	(617)275-8374
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6177287100
Email:	BOSpatents@dechert.com, Daphne.Cashion@dechert.com
Correspondent Name:	DECHERT LLP
Address Line 1:	ONE INTERNATIONAL PLACE, 40TH FLOOR
Address Line 2:	100 OLIVER STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	403433-005USC1 (193334)
NAME OF SUBMITTER:	ANDREA L.C. REID
SIGNATURE:	/Andrea L.C. Reid/
DATE SIGNED:	12/20/2022
Total Attachments: 3	
source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Nuchem#page1.tif	
source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Nuchem#page2.tif	
source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Nuchem#page3.tif	

**COMBINED DECLARATION (37 CFR § 1.63) AND ASSIGNMENT (DUAL PURPOSE)
FOR UTILITY OR DESIGN PATENT APPLICATION USING AN APPLICATION DATA SHEET**

DECLARATION:

The within-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

ASSIGNMENT:

WHEREAS, we, the undersigned,

Maxence BOS of c/o NuChem Therapeutics Inc., 2350 Cohen Street, Suite 201, Saint-Laurent, Quebec H4R 2N6, CANADA;

John MANCUSO, of c/o NuChem Therapeutics Inc., 2350 Cohen Street, Suite 201, Saint-Laurent, Quebec H4R 2N6, CANADA;

Ivan FRANZONI, of c/o NuChem Therapeutics Inc., 2350 Cohen Street, Suite 201, Saint-Laurent, Quebec H4R 2N6, CANADA;

are inventors of the invention described and claimed in "**HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE**" and hereby execute an application for a patent of the United States, having Application No. 17/302,502, filing date of **May 4, 2021**, and

are also aware of the following priority applications:

63/019,772, filing date of **May 4, 2020**

WHEREAS, NuChem Therapeutics Inc. (hereinafter termed "Assignee"), having a place of business at **2350 Cohen Street, Suite 201, Saint-Laurent, Quebec H4R 2N6, CANADA**, desires to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by us (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, receipt and sufficiency of which is acknowledged by us to have been received in full from said Assignee:

1. We do hereby sell, assign, transfer and convey unto said Assignee, and/or confirm prior assignment, transfer, or conveyance unto said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.


2. We hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by us shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by us in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon us, our respective heirs, legal representatives and assigns.

4. We hereby warrant and represent that we have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, we have executed and delivered this instrument to said Assignee.

NuChem Therapeutics Inc. ("Assignee")

By: 


Name: JOHN MANCUSO

Title: PARTNER

Date: MAY 17/2021

WITNESSES

Signature: 

Signature: 

By: <u>Maxence BOS</u> Maxence BOS Date: <u>May 17th 2021</u> WITNESSES: Signature: <u>[Signature]</u> Signature: <u>[Signature]</u>	By: <u>John MANCUSO</u> John MANCUSO Date: <u>MAY 17/2021</u> WITNESSES: Signature: <u>[Signature]</u> Signature: <u>[Signature]</u>
By: <u>Ivan FRANZONI</u> Ivan FRANZONI Date: <u>May 17 2021</u> WITNESSES: Signature: <u>[Signature]</u> Signature: <u>[Signature]</u>	